⚠ STRICT REGULATORY DIRECTIVE: B2B API SUPPLY ONLY

Shaanxi Sunrise Pharmaceutical Co., Ltd. operates strictly as an industrial API supplier. The Carboplatin (CAS: 41575-94-4) technical data provided below is exclusively directed at Formulation Scientists, QA/QC Directors, and Pharmaceutical Procurement Managers. This organometallic raw material is intended for R&D, laboratory, and commercial manufacturing scale-up only. It is NOT a finished drug product and is strictly prohibited for direct patient administration.

For decades, the recalibration of metallic salts has defined systemic oncology. However, for global API procurement entities and formulation scientists navigating the 2026 manufacturing landscape, Carboplatin is vastly more than just a historical breakthrough. It remains an indispensable, highly sensitive organometallic coordination complex requiring absolute purity and flawless logistical handling.

By modulating the stability of the platinum-DNA interaction, Carboplatin successfully widens the therapeutic window, largely replacing the extreme nephrotoxicity and emetogenesis associated with first-generation cisplatin. At Shaanxi Sunrise, we provide this technical deep-dive into its intracellular mechanics, clinical backbone status, and the draconian quality control requirements necessary for modern B2B supply chains.

The pharmacological identity of Carboplatin—cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)—is predicated on its bidentate 1,1-cyclobutanedicarboxylate ligand. This specific structural nuance is not merely cosmetic; it acts as a precise molecular brake, fundamentally altering the drug's pharmacokinetic profile compared to its highly reactive predecessor, cisplatin.

Unlike earlier generations of platinum agents that react unpredictably with plasma proteins in the bloodstream, Carboplatin remains largely stable in systemic circulation. It transforms into a highly reactive electrophile only upon crossing the cell membrane and encountering the low-chloride microenvironment of the neoplastic cell. The slow hydrolysis (aquation) of the cyclobutane ring unleashes the active platinum species. The resulting nucleophilic strike on the N7 atoms of guanine and adenine residues creates lethal intrastrand DNA adducts, arresting replication at the G2/M checkpoint and triggering irreversible apoptosis.

For procurement engineers, this mechanism dictates API stability requirements. If the API is exposed to moisture or extreme heat during synthesis or transit, premature aquation occurs, generating highly toxic degradants and destroying the API's therapeutic viability before it ever reaches your compounding tanks.

In the 2026 clinical landscape, high-purity Carboplatin remains the immutable backbone for several critical, high-volume indications:

• The Ovarian Oncology Anchor: The "platinum-doublet" (Carboplatin paired synergistically with taxanes like Paclitaxel) is the undisputed international benchmark for advanced ovarian carcinoma. The Platinum-Free Interval (PFI) remains the ultimate prognostic biomarker for recurrent disease sensitivity.

• Respiratory Oncology (NSCLC): For Non-Small Cell Lung Cancer patients whose renal profiles or baseline neuropathies preclude aggressive cisplatin derivatives, Carboplatin provides a vital, tolerable therapeutic avenue without sacrificing objective response rates.

• Combinatorial Synergy (PD-1 Blockade): Current R&D pipelines focus heavily on pairing Carboplatin with Immune Checkpoint Blockade (ICB) therapies, such as Pembrolizumab. The cytotoxic destruction of tumor cells by Carboplatin induces neoantigen release, priming the tumor microenvironment for immunotherapeutic targeting. This creates a massive, ongoing B2B demand for stable, pharmaceutical-grade API for clinical trials.

A hallmark of Carboplatin formulation and clinical application is the absolute reliance on renal clearance metrics to prevent dose-limiting toxicity—specifically, severe thrombocytopenia (platelet depletion) and myelosuppression. The global standard for personalized dosing is the Calvert Formula:

B2B Formulation Insight: Because the therapeutic dose is mathematically locked to the patient's Glomerular Filtration Rate (GFR) and the target Area Under the Curve (AUC), the baseline purity and exact platinum content of your API are profoundly critical. Even a 0.5% variation in API assay or the presence of inert residual solvents can throw off mass-based pharmacokinetic modeling, leading to either sub-therapeutic dosing or catastrophic hematopoietic failure.

Manufacturing injectable Carboplatin solutions requires hyper-vigilance regarding excipient and equipment compatibility. Formulators must audit their production lines for two lethal chemical interactions:

• Aluminum Reactivity: Carboplatin API reacts aggressively with aluminum. If the API or the final formulated solution comes into contact with aluminum-hubbed needles or aluminum components in the filling line, it instantly precipitates out as a black platinum oxide degradation product. This causes a total, irreversible loss of antineoplastic potency.

• Chloride Degradation: Unlike cisplatin, Carboplatin formulations must strictly avoid chloride-containing diluents (such as 0.9% Sodium Chloride). The presence of chloride ions accelerates the degradation of the cyclobutane ring, forcing the Carboplatin molecule to revert into highly toxic cisplatin-like species, ruining the safety profile of the batch. Solutions must be formulated exclusively with 5% Dextrose or Water for Injection (WFI).

Audit our 2026 physical and chemical release specifications. Shaanxi Sunrise enforces testing protocols that exceed baseline pharmacopeial minimums:

Q: How does Shaanxi Sunrise ensure the stability of Carboplatin API during international transit?
Organometallic complexes require precise, unyielding environmental controls. We utilize highly validated, multi-layered pharmaceutical packaging. The API is sealed within double antistatic polyethylene bags, vacuum-purged, and housed inside light-resistant aluminum foil pouches. This barrier completely protects the API from moisture and photolytic degradation, ensuring the cyclobutanedicarboxylate ligand remains structurally intact upon arrival at your GMP facility.

Q: Is your Carboplatin suitable for advanced delivery platform R&D?
Yes. With the oncology industry heavily shifting toward Nanoparticle Encapsulation to leverage the Enhanced Permeability and Retention (EPR) effect, formulation tolerances are shrinking. Our ultra-high purity (≥ 99.5%) API minimizes the presence of secondary salts and transition metals that could permanently destabilize your highly sensitive liposomal or polymeric nanocarriers.

Q: Do you provide full regulatory documentation for global import?
Absolutely. For over a decade, Shaanxi Sunrise has flawlessly navigated global pharmaceutical logistics and customs clearance. We provide comprehensive Certificates of Analysis (COAs), Material Safety Data Sheets (MSDS), detailed Route of Synthesis (RoS) documents, and real-time stability testing data to streamline your regulatory ANDA or IND submissions.

Do not compromise your oncology pipeline with unverified metallic intermediates. Secure reliable, high-purity Carboplatin (CAS 41575-94-4) directly from a proven manufacturer. Request batch-specific COAs, impurity profiling, and current B2B global pricing.

• Supplier: Shaanxi Sunrise Pharmaceutical Co., Ltd.

• Quality System: ISO 9001:2015 / GMP Certified Facility

• Web: www.pharma-sunrise.com

• Email: betty@pharma-sunrise.com

• Direct: +86 18092760627

• Calvert, A. H., et al. "Carboplatin dosage: Real-time monitoring and the Calvert formula." Journal of Clinical Oncology.

• EMA Guidelines: "Assessment Report: Carboplatin Quality and Regulatory Guidelines."

• FDA Database: Carboplatin Injection Prescribing Information & Black Box Warnings.

• Shaanxi Sunrise Pharmaceutical Co., Ltd. Internal QA Documentation.